Fertility has become one of the clearest examples of consolidation in European healthcare. Demand is rising structurally, the market remains fragmented across independent and small clinic groups, and private equity has moved in to scale.

The evidence from the United States shows where this can lead. A study published in Fertility and Sterility found that clinics affiliated with private equity or venture capital now perform most IVF cycles in the country, having grown to around a third of all clinics. Europe is earlier in the same process but moving quickly. The purchase of IVIRMA by KKR stands as the largest private equity transaction the sector has seen, and platforms such as Indira IVF and Eugin, a group based in Barcelona that operates clinics in several countries, have changed hands as buyers assemble networks across more than one market.

The logic is familiar from other roll ups. Scaled operators bring capital for equipment and laboratories, centralised administration, and data systems that can support better success rates, while acquiring fragmented single site clinics at lower entry multiples.

For clinic group owners, the implication is that the best assets, generally groups with several sites, strong outcomes and their own laboratory or data capability, command premiums in this market. For acquirers, the runway of independent clinics still available to consolidate is long. Rising regulatory and ethical scrutiny of private ownership in reproductive medicine should be reviewed in diligence and reputational consideration.

We expect European fertility consolidation to continue, with the most sought after assets being those that combine clinical quality with the systems to scale. As in any roll up, the owners who move while buyer appetite is high tend to achieve the best outcomes.

#PrivateEquity

#CorporateFinance

#Fertility